CHCWM – Cancer & Hematology Centers of West Michigan

QED (PROOF)

A Phase III Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib vs. Cis/Gem in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations.

Principal Investigator: Dr. Sreenivasa Chandana

For more information on this trial, read its profile on clinicaltrials.gov here.